Executive summary
US Patent 8,410,102 is a method-of-treatment patent for topical aqueous gels using an α-adrenergic receptor agonist at broad concentration ranges to treat erythema, with dependent claim coverage narrowing to rosacea and specific actives (notably brimonidine and oxymetazoline) plus gel formulation variables (gelling agent/carbomer). The claim set is structurally positioned to cover: (i) rosacea erythema treatment by once-daily topical aqueous gel containing an α-agonist in a wide 0.01–10% w/w window, (ii) multiple α1/α2-selectivity categories, and (iii) common de-gel options via gelling agent and carbomer ranges. Practically, competitors face two key patent-limiting vectors: Paragraph IV-style “carve-outs” by stepping outside concentration and/or formulation defining ranges or by using non-α-agonist actives; and design-around risk from the claim’s broad genus selection of α-agonists and its functional “selective/non-selective” receptor language.
US Patent 8,410,102 landscape: What patents protect topical aqueous gel methods treating erythema with alpha-adrenergic receptor agonists?
US 8,410,102 claim scope is centered on a single therapeutic mechanism class and a single dosage form architecture: topically administered topical aqueous gel containing an α-adrenergic receptor agonist at 0.01% to 10% by weight in a pharmaceutically acceptable carrier for treating erythema or a symptom associated therewith on skin that is affected or prone to be affected.
What is the core independent claim 1 scope?
Claim 1 requires all elements below:
- Use type: “A method of treating erythema or a symptom associated therewith”
- Route/dosage form: topical administration to a skin area using a topical aqueous gel composition
- Actives: “at least one α-adrenergic receptor agonist”
- Concentration: ~0.01% to ~10% by weight
- Form: includes a “pharmaceutically acceptable carrier”
- Condition linkage: skin area is “affected by the erythema or the symptom associated therewith” or “prone to be affected”
Claim 1 is genus-broad across:
- erythema etiology (not limited to rosacea)
- receptor selectivity (covered later as dependent options)
- α-agonist identity (covered broadly by dependent lists, but genus is already functionally defined)
- gel vehicle (only “aqueous gel” plus carrier)
- treatment regimen (once daily appears only in a dependent claim)
Featured-snippet answer: the claim’s “lock points”
The claim’s enforceable lock points are:
- topical aqueous gel
- α-adrenergic receptor agonist
- 0.01%–10% w/w
- treating erythema (or symptom) on a skin area
How do dependent claims narrow claim 1?
Claim 2 anchors rosacea specifically:
- Claim 2: erythema is “erythema of rosacea”
Claims 3–5 create receptor-selectivity buckets:
- Claim 3: α1-selective agonist
- Claim 4: α2-selective agonist
- Claim 5: non-selective α-agonist
Claims 6–9 identify representative actives:
- Claim 6: brimonidine
- Claim 7: oxymetazoline
- Claim 8: naphazoline
- Claim 9: selected list: tetrahydrozoline, xylometazoline, phenylephrine, methoxamine, mephentermine, metaraminol, midodrine, epinephrine, norepinephrine
Claim 10 adds combination therapy:
- “further comprising administering… at least one additional treatment and medication for erythema…”
Claims 11–13 add regimen and formulation constraints:
- Claim 11: administered once daily
- Claim 12: gel includes gelling agent ~0.20%–4.0% w/w
- Claim 13: gel includes carbomer ~0.50%–2.0% w/w
Practical read-through for infringement risk
- A competitor gel using any α-agonist in the 0.01%–10% w/w window can fall within claim 1 even without being carbomer-based or once-daily.
- Carboxyvinyl polymers/carbomer and once-daily dosing become relevant mainly for dependent claims, strengthening coverage if a product tracks those specifics.
Which α-adrenergic receptor agonists are explicitly covered by US 8,410,102?
Explicitly named agonists (dependent claim list)
US 8,410,102 gives explicit coverage for:
- brimonidine
- oxymetazoline
- naphazoline
- tetrahydrozoline
- xylometazoline
- phenylephrine
- methoxamine
- mephentermine
- metaraminol
- midodrine
- epinephrine
- norepinephrine
What does the functional “α-adrenergic receptor agonist” genus add?
Even where specific actives are named, claim 1 already captures “at least one α-adrenergic receptor agonist.” That functional language expands coverage to other α-agonists not listed, provided they are α-adrenergic receptor agonists and used in the claimed topical aqueous gel and 0.01–10% w/w concentration range.
How do α1/α2 selectivity options matter for design-around?
Dependent claims 3 and 4 create alternative, not limiting, routes to infringement. If a competitor argues it uses an α-agonist that is not α1-selective or α2-selective, claim 5 and claim 1’s genus typically still preserve infringement risk.
What formulations are protected: aqueous gels, gelling agent range, and carbomer limits?
Aqueous gel requirement
Claim 1 is limited to a “topical aqueous gel composition.” That implies:
- a gel matrix with predominantly aqueous character
- topical delivery system shaped as a gel rather than cream, ointment, foam, or lotion
Gelling agent and carbomer dependent ranges
- Claim 12: gelling agent 0.20%–4.0% w/w
- Claim 13: carbomer 0.50%–2.0% w/w
Formulation design-around logic (within the patent’s claim structure)
- To avoid dependent claim 13, a product must be outside the stated carbomer w/w range while still potentially risking claim 1.
- To avoid dependent claim 12, a product must be outside the stated gelling-agent range while still potentially risking claim 1.
- To avoid claim 1, a competitor must change at least one of: (i) gel type away from “aqueous gel,” (ii) active type away from α-agonists, (iii) concentration outside 0.01–10% w/w, or (iv) therapeutic method away from treating erythema/symptoms as claimed.
When does US 8,410,102 expire and how can exclusivity interact with patent protection?
US Patent 8,410,102 is a utility patent issued on its patent number date, but no filing date, priority date, or jurisdictional term details are provided in the prompt. Without those dates, an accurate expiration timeline (20-year term from earliest effective filing, PTA adjustments, and maintenance status) cannot be computed.
Key exclusivity question (cannot be answered from provided data)
The patent’s enforceability against FDA-approvable products can also be affected by:
- Orange Book-listed drug product patent(s)
- whether the method is tied to an NDA/BLA approval
- exclusivity periods (3/5/7 years) that delay generic/biosimilar approval
No FDA product identity or Orange Book listing is provided, so the exclusivity interaction cannot be stated reliably.
What generic entry risks exist for α-adrenergic topical gels targeting rosacea erythema?
Claim-driven entry risk categories
US 8,410,102 creates entry risk for products that:
- compete with topical treatments for erythema (especially rosacea)
- use α-adrenergic agonists in a topical aqueous gel format
- keep active concentration within 0.01%–10% w/w
High-risk features to watch in ANDA/505(b)(2) development
- α-agonist selection: brimonidine-class and oxymetazoline-like actives align with named examples and general genus
- concentration: any formulation inside 0.01%–10% w/w
- dosage form: topical aqueous gel (not a non-gel delivery system)
- intended use language: “treating erythema” or “symptom associated therewith” in labeling and/or clinical dosing instructions
Paragraph IV litigation exposure (pattern, not a case-specific record)
Given the breadth of claim 1, a Paragraph IV strategy would typically attack one of the claim elements. For this patent specifically, the most plausible litigation attack points are:
- challenge the active as not being an “α-adrenergic receptor agonist” as asserted
- challenge concentration evidence (outside 0.01%–10% w/w)
- challenge dosage form (not an “aqueous gel” as characterized)
- challenge method “treating erythema” nexus (labeling/carve-out arguments)
- invalidate claims based on prior art or lack of written description/enablement (analysis requires the actual specification and prior art set)
A case docket analysis (case number, parties, asserted patents, settlement terms) cannot be provided from the prompt.
How does US 8,410,102 compare with patent estates for related rosacea alpha-agonist products?
What can be compared using claim language alone
US 8,410,102 is positioned as a topical aqueous gel method patent that:
- covers multiple α-agonists
- supports rosacea as a dependent narrowing
- includes straightforward formulation constraints (gelling agent and carbomer ranges)
This claim structure is consistent with a patent strategy around generic “design-around resistance” by using:
- broad α-agonist genus language
- wide concentration range
- formulation ranges that map to common gel engineering (carbomer use)
What cannot be compared without identifying the relevant commercial products
A product-by-product comparison requires:
- which drug products are Orange Book-listed for method/use and formulation patents
- their active concentration and gel composition
- which patents overlap with 8,410,102
No NDA/BLA name, NDC, or Orange Book entries are provided, so no accurate cross-estate ranking can be produced.
Patent scope map: which product variants fall inside vs outside the claims?
Likely “inside claim 1” scenario set
A topical aqueous gel containing an α-adrenergic receptor agonist at 0.01%–10% w/w, applied to skin area affected by erythema or prone to erythema, with labeling or method guidance directed to treating erythema or related symptoms.
Likely “inside dependent claims” scenario set
- Uses brimonidine or oxymetazoline (directly named)
- Shows rosacea erythema as the target condition
- Uses once-daily administration
- Uses gelling agent concentration 0.20%–4.0% w/w
- Uses carbomer 0.50%–2.0% w/w
- Uses α1-selective or α2-selective agonist as framed
Likely “design-around candidates” based on claim structure
- Reformulate into a non-gel topical dosage form (or non-aqueous gel character) to avoid “topical aqueous gel”
- Switch to non-α-adrenergic receptor agonist actives
- Keep α-agonist outside 0.01%–10% w/w
- Adjust labeling/method intent away from “treating erythema” or from “symptom associated therewith”
- Use gel system outside carbomer and/or gelling agent ranges (still risks claim 1)
What litigation affects US 8,410,102 and how strong is the patent estate for erythema gels?
No litigation or enforcement history is provided in the prompt. Strength scoring typically requires:
- claim construction outcomes
- validity challenges and prior art determinations
- prosecution history (file wrapper)
- specification support and enablement findings
- court holdings on enforceability and scope
Without those records, a scorecard would be speculative and cannot be produced under the constraint to provide complete and accurate response.
Key Takeaways
- US 8,410,102 claim 1 is a broad method-of-treatment claim for topical aqueous gels containing α-adrenergic receptor agonists at 0.01%–10% w/w to treat erythema or its symptoms on affected or at-risk skin.
- Dependent claims strengthen coverage for rosacea and for specific actives including brimonidine and oxymetazoline, plus α1/α2-selectivity categories.
- Formulation dependencies on gelling agent (0.20%–4.0% w/w) and carbomer (0.50%–2.0% w/w) create additional infringement hooks if a candidate product matches those ranges.
- The principal design-around axes are structural: dosage form characterization, active class, and concentration window, followed by labeling/method-intent and gel polymer ranges.
FAQs
What if a competitor uses an α-agonist outside 0.01%–10% w/w?
The answer is governed by claim 1’s concentration limitation; leaving the 0.01%–10% w/w range avoids claim 1 but may still face other patents covering alternative dosing.
Does US 8,410,102 cover combination therapy for erythema?
Yes. Claim 10 allows adding additional treatments and medications without removing coverage.
Can a product avoid infringement by using a different gel polymer instead of carbomer?
Avoiding claim 13 is possible by moving outside the carbomer range. Claim 1 still may apply because it does not require carbomer.
Is rosacea required to infringe?
No. Claim 1 covers erythema generally; rosacea is a dependent narrowing in claim 2.
Are once-daily dosing and gelling-agent percentages required?
No. Once-daily dosing is in claim 11 and gelling agent/carborner ranges are in claims 12 and 13. Those details matter for dependent coverage, not claim 1.
References
- US Patent 8,410,102. (Provided claims text in prompt).
